Passive Immunization with Hypochlorite-oxLDL Specific Antibodies Reduces Plaque Volume in LDL Receptor-Deficient Mice

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  van Leeuwen, Marcella ^a   Kemna, Michael J ^a   de Winther, Menno P J ^a,b   Boon, Louis ^c   Duijvestijn, Adriaan M ^a   Henatsch, Darius ^a   Bos, Nico A ^d   Gijbels, Marion J J ^a,b   Tervaert, Jan Willem Cohen ^a,e  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c BIOCEROS   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HISTIDINE; HYPOCHLORITE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A7S8; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; LIPID DIET; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN DEPLETION;

ANIMALS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; IMMUNOGLOBULIN M; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, LDL;

EID: 84880474367     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068039     Document Type: Article

References (41)

1. Charo IF, Taub R, (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 10: 365-376.
2. Hansson GK, Libby P, (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
3. Chyu KY, Nilsson J, Shah PK, (2007) Active and passive immunization for atherosclerosis. Curr Opin Mol Ther 9: 176-182.
4. van Leeuwen M, Damoiseaux J, Duijvestijn A, Tervaert JW, (2009) The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun Rev 9: 53-57.
5. Faria-Neto JR, Chyu KY, Li X, Dimayuga PC, Ferreira C, et al. (2006) Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189: 83-90.
6. Binder CJ, Chou MY, Fogelstrand L, Hartvigsen K, Shaw PX, et al. (2008) Natural antibodies in murine atherosclerosis. Curr Drug Targets 9: 190-195.
7. Binder CJ, Shaw PX, Chang MK, Boullier A, Hartvigsen K, et al. (2005) Thematic review series: The Immune System and Atherogenesis. The role of natural antibodies in atherogenesis. J Lipid Res 46: 1353-1363.
8. Shaw PX, Horkko S, Tsimikas S, Chang MK, Palinski W, et al. (2001) Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21: 1333-1339.
9. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, et al. (2004) IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114: 427-437.
10. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, et al. (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9: 736-743.
11. Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S, (2003) Immunoglobulin M Type of Autoantibodies to Oxidized Low-Density Lipoprotein Has an Inverse Relation to Carotid Artery Atherosclerosis. Circulation 108: 2107-2112.
12. Su J, Georgiades A, Wu R, Thulin T, de Faire U, et al. (2006) Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188: 160-166.
13. Frostegård J, (2010) Low level natural antibodies against phosphorylcholine: A novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clinical Immunology 134: 47-54.
14. Caidahl K, Hartford M, Karlsson T, Herlitz J, Pettersson K, et al. (2012) IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes. Int J Cardiol.
15. Nicholls SJ, Hazen SL, (2005) Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25: 1102-1111.
16. Podrez EA, Schmitt D, Hoff HF, Hazen SL, (1999) Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103: 1547-1560.
17. Daugherty A, Dunn JL, Rateri DL, Heinecke JW, (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437-444.
18. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, et al. (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349: 1595-1604.
19. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, et al. (2001) Association between myeloperoxidase levels and risk of coronary artery disease. Jama 286: 2136-2142.
20. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA, (2004) Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 116: 429-430.
21. Slot MC, Theunissen R, van Paassen P, Damoiseaux JG, Cohen Tervaert JW, (2007) Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins. Clin Exp Immunol 149: 257-264.
22. van Leeuwen M, Damoiseaux J, Duijvestijn A, Heeringa P, Gijbels M, et al. (2009) The IgM response to modified LDL in experimental atherosclerosis: hypochlorite-modified LDL IgM antibodies versus classical natural T15 IgM antibodies. Ann N Y Acad Sci 1173: 274-279.
23. Rouhl RPW, van Oostenbrugge RJ, Theunissen ROMFIH, Knottnerus ILH, Staals J, et al. (2010) Autoantibodies Against Oxidized Low-Density Lipoprotein in Cerebral Small Vessel Disease. Stroke 41: 2687-2689.
24. van Leeuwen M, Gijbels MJ, Duijvestijn A, Smook M, van de Gaar MJ, et al. (2008) Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol 28: 84-89.
25. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
26. Smook M, van Leeuwen M, Damoiseaux J, Theunissen R, Daemen M, et al. (2008) anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE-/- and APOE-/-CD40L-/- mice. Clin Exp Immunol 154: 264-269.
27. Orlandi R, Gussow DH, Jones PT, Winter G, (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U S A 86: 3833-3837.
28. Stoel M, Jiang HQ, van Diemen CC, Bun JC, Dammers PM, et al. (2005) Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasmablasts. J Immunol 174: 1046-1054.
29. Giudicelli V, Chaume D, Lefranc MP, (2004) IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 32: W435-440.
30. von der Thusen JH, van Berkel TJ, Biessen EA, (2001) Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 103: 1164-1170.
31. Goossens P, Gijbels M, Zernecke A, Eijgelaar W, Vergouwe M, et al. (2010) Myeloid Type I Interferon Signaling Promotes Atherosclerosis by Stimulating Macrophage Recruitment to Lesions. Cell Metabolism 12: 142-153.
32. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, et al. (2003) Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 112: 1176-1185.
33. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, et al. (2009) Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 119: 1335-1349.
34. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, et al. (2007) Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 50: 159-165.
35. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, et al. (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100: 2995-3004.
36. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, et al. (2008) Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133: 235-249.
37. de Faire U, Su J, Hua X, Frostegård A, Halldin M, et al. (2010) Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: Effects on uptake of oxidized LDL in macrophages as a potential mechanism. Journal of Autoimmunity 34: 73-79.
38. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, et al. (2007) Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 50: 540-546.
39. Cesena FHY, Dimayuga PC, Yano J, Zhao X, Kirzner J, et al. (2012) Immune-modulation by polyclonal IgM treatment reduces atherosclerosis in hypercholesterolemic apoE-/- mice. Atherosclerosis 220: 59-65.
40. Habets KLL, van Puijvelde GHM, van Duivenvoorde LM, van Wanrooij EJA, de Vos P, et al. (2010) Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovascular Research 85: 622-630.
41. Ehrenstein MR, O'Keefe TL, Davies SL, Neuberger MS, (1998) Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proc Natl Acad Sci U S A 95: 10089-10093.